Rosiglitazone, a selective PPARγ activator, did not ameliorate NASH, but inhibited lipogenesis in the rosiglitazone therapy (FLIRT 2) extension trial (Ratziu et al., 2010). Here, PPARG is linked to metabolic dysfunction-associated steatohepatitis.